G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, and Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, announce that they have entered into a definitive merger agreement under which Pharmacosmos A/S, through its U.S. subsidiary Pharmacosmos Therapeutics Inc., will acquire all outstanding shares of G1 Therapeutics common stock for U.S. $7.15 per share in cash for a total equity value of approximately $405 million.
Read the full article: Pharmacosmos Group to Acquire G1 Therapeutics //
Source: https://www.globenewswire.com/news-release/2024/08/07/2925767/0/en/Pharmacosmos-Group-to-Acquire-G1-Therapeutics.html